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Abstract NADPH oxidase has been shown to play an
important role in cardiovascular biology. The goal of the present
study was to determine whether NADPH oxidase activity is
important for endothelial cell growth and migration. In
proliferation assays, growth factor- or serum-induced DNA
synthesis in three different types of human endothelial cells was
abrogated by inhibitors of NADPH oxidase, but not by inhibitors
of xanthine oxidase or nitric oxide synthase. Moreover, vascular
endothelial growth factor-induced migration of human endothe-
lial cells was suppressed in the presence of NADPH oxidase
inhibitors. These results support a potential role for NADPH
oxidase in mediating angiogenesis. ß 2000 Federation of Euro-
pean Biochemical Societies. Published by Elsevier Science B.V.
All rights reserved.
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1. Introduction
Superoxide and other reactive oxygen species (ROS) have
been implicated in the initiation and progression of several
vascopathic disease states. At the same time, ROS are now
recognized to play an important role as signal transduction
intermediates [1^4]. Several intracellular sources contribute to
the production of ROS, including cyclooxygenases, cyto-
chrome P450, endothelial nitric oxide synthase (NOS), lipoxy-
genases, mitochondrial respiration, NADPH oxidase, and
xanthine oxidase.
Recent studies have underscored the importance of
NADPH oxidase-derived ROS in vascular biology. Many
components of the leukocyte NADPH oxidase complex, in-
cluding p22phox, p47phox, p67phox and gp91phox (or a re-
lated homologue), have been identi¢ed in endothelial cells or
vascular smooth muscle cells (VSMC) [5^9]. In VSMC,
NADPH oxidase activity has been shown to increase in re-
sponse to thrombin [8], angiotensin II [10,11], platelet-derived
growth factor (PDGF) [12], and tumor necrosis factor-K [13].
In endothelial cells, activation of NADPH oxidase has been
reported to occur in response to oscillatory and steady state
shear stress [14], cyclical strain [15], ischemia [16,17], or high
concentrations of K [16].
In the present study, we show that endothelial cell prolifer-
ation and migration require NADPH oxidase activity. These
results suggest that endothelial cell growth is tightly coupled
to the redox state of the cell. Moreover, the ¢ndings imply
that the inhibition of NADPH oxidase activity may provide a
foundation for anti-angiogenic therapy.
2. Materials and methods
2.1. Cell proliferation assays
Human coronary endothelial cells (HCAEC), human dermal micro-
vascular endothelial cells (HDMVEC) and human umbilical vein en-
dothelial cells (HUVEC) (Clonetics) were grown to con£uence in En-
dothelial Cell Growth Medium-2-MV BulletKit (Clonetics) and
seeded in 24-well plates at a density of 4U104/well. The following
day, the cells were serum-starved for 7 h in Endothelial Cell Basal
Medium-2 (EBM-2) containing 0.5% fetal bovine serum (FBS) and
then treated for 24 h with 0.5% FBS, 10 ng/ml vascular endothelial
growth factor (VEGF) (Peprotech), 5 ng/ml bFGF (Peprotech) or 5%
FBS in the presence or absence of the NADPH oxidase inhibitors,
DPI (Biomol) [18], apocynin (Aldrich) [19], or 4-(2-aminoethyl)-ben-
zenesulfonyl £uoride (AEBSF; Sigma) [20]; the xanthine oxidase in-
hibitor, allopurinol (Sigma); or the NOS inhibitor L-NAME (Sigma)
at the doses indicated. [3H]Thymidine (1 WCi/well, 20 Ci/mmol) was
added during the last 4 h of incubation. Cells were rinsed with phos-
phate bu¡er solution, trypsinized and radioactivity was extracted with
0.2 N NaOH. [3H]Thymidine incorporation was measured by count-
ing an aliquot of cell extract in an automated liquid scintillation
counter.
2.2. Cell migration assays
Migration assays were carried out in a modi¢ed Boyden chamber
(Neuro Probe). HCAEC were serum-starved overnight in EBM-2 me-
dium containing 0.5% FBS. The bottom 48-well plate was ¢lled with
EBM-2 medium containing 0.2% FBS with or without 50 ng/ml
VEGF in the presence or absence of DPI, apocynin, AEBSF, allopur-
inol or L-NAME at the doses indicated. A polycarbonate ¢lter pre-
treated with 13.5 Wg/ml ¢bronectin (Sigma) was laid over the bottom
plate and then covered with the top plate. HCAEC were pre-incu-
bated in EBM-2 medium containing 0.2% FBS in the presence or
absence of the same inhibitors for 10 min and then added to the
top well at a density of 7500 cells/well. The chamber was incubated
at 37‡C for 4 h. The cells were ¢xed and stained with Di¡-Quik (Dade
Behring). The cells on the top of the membrane were removed and the
cells that had migrated to the bottom side were counted under light
microscopy. Counts are reported as an average of cell number per
mm2 (n = 6^12 per condition).
2.3. ROS generation
Changes in intracellular ROS levels were determined by measuring
the oxidative conversion of cell permeable 2P,7P-dichloro£uorescein
diacetate (DCFH-DA; Molecular Probes) to £uorescent dichloro-
£uorescein (DCF) in £uorescence-activated cell sorting (FACS) assays
as previously described [21]. HCAEC were grown to 95% con£uence,
incubated with control media (C) or 50 ng/ml VEGF for 1 h in the
absence or presence of 100 WM DPI, 500 WM L-NAME or 100 WM
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allopurinol. The cells were washed with HBSS and incubated with
DCFH-DA at 37‡C for 30 min. DCF £uorescence distribution of
20 000 cells was detected by FACS analysis at an excitation wave-
length of 485 nm and at an emission wavelength of 530 nm. Propi-
dium iodide-positive cells were excluded from the analysis.
3. Results
3.1. Endothelial cell proliferation is dependent on NADPH
oxidase activity
The incubation of serum-starved HCAEC with 10 ng/ml
VEGF resulted in a 1.4-fold induction of thymidine uptake
(Fig. 1A). Pretreatment of HCAEC with 10 WM DPI
(NADPH oxidase/NOS inhibitor) resulted in a dramatic re-
duction in VEGF-induced thymidine incorporation below
basal levels, whereas pretreatment with 100 WM allopurinol
(xanthine oxidase inhibitor) or 500 WM L-NAME (NOS in-
hibitor) had no signi¢cant e¡ect (Fig. 1A). bFGF- or serum-
mediated induction of cell proliferation (1.5-fold and 1.7-fold,
respectively) was also abrogated by pre-incubation with 10
WM DPI, but not with allopurinol or L-NAME (Fig. 1B,C).
DPI-mediated inhibition of DNA synthesis was dose-depen-
dent (Fig. 2A). Moreover, proliferation of HCAEC was sup-
pressed in a dose-dependent manner by two other inhibitors
of NADPH oxidase, apocynin and AEBSF (Fig. 2B,C). In
HDMVEC, VEGF-, bFGF- and serum-induced thymidine in-
corporation was signi¢cantly blunted by 10 WM DPI, but not
by allopurinol or L-NAME (Fig. 3A^C). Similar results were
obtained with HUVEC cells (Fig. 3D shows serum response).
Taken together, these results suggest that both basal and
stimulated endothelial cell proliferation are dependent upon
NADPH oxidase activity.
3.2. Endothelial cell migration is dependent on NADPH
oxidase activity
HCAEC migration was induced 1.5^3-fold in the presence
of 50 ng ml VEGF (Fig. 4A^C). This response was abrogated
Fig. 1. Thymidine incorporation in HCAEC is decreased by
NADPH oxidase inhibitor. [3H]Thymidine incorporation was mea-
sured in untreated HCAEC (0.5%) or in HCAEC treated with (A)
10 ng/ml VEGF (V), (B) 5 ng/ml bFGF (bF) or (C) 5% FBS (5%)
in the absence or presence of 10 WM DPI (+DPI), 100 WM allopuri-
nol (+Allo) or 500 WM L-NAME (+L). Blank represents back-
ground counts from unseeded wells. [3H]Thymidine incorporation is
expressed as mean þ S.D. from four samples. *P6 0.05 compared
with control, untreated cells. 2P6 0.05 compared with treated cells.
Fig. 2. Decrease in thymidine incorporation by NADPH oxidase inhibitors is dose-dependent. [3H]Thymidine incorporation was measured in
untreated HCAEC (0.5%) or in HCAEC treated with 5% FBS in the presence or absence of increasing doses of (A) DPI, (B) apocynin or (C)
AEBSF.
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by the addition of 10 WM DPI or 300 WM apocynin (Fig.
4A,B). Moreover, both basal and VEGF-induced migration
were inhibited by 250 WM AEBSF (Fig. 4C). HCAEC migra-
tion was inhibited by DPI (Fig. 5A) and AEBSF (Fig. 5B) in
a dose-dependent manner. In contrast, the addition of L-
NAME or allopurinol had no e¡ect on chemotaxis (Fig.
4B,C).
3.3. ROS generation in VEGF-treated HCAEC is inhibited
speci¢cally by NADPH oxidase inhibitors
We have previously shown that VEGF does not induce
ROS generation in endothelial cells (Abid et al., unpublished
observations). To determine whether the results of the prolif-
erative assays correlated with changes in intracellular ROS
generation, we measured DCF £uorescence in VEGF-treated
HCAEC in the presence or absence of ROS antagonists. The
arithmetic means (control cells arbitrarily set at 100) þ S.D.
of DCF £uorescence from three independent experiments
were as follows: no treatment, 100 þ 3.5; VEGF, 83 þ 6;
VEGF+DPI, 23.5 þ 2; VEGF+L-NAME, 93.6 þ 2.8; VEG-
F+allopurinol, 78.2 þ 6. Representative histograms are shown
in Fig. 6.
4. Discussion
Previous studies have established an important role for
ROS in cell proliferation. For example, in VSMC, ROS
have been implicated in the mitogenic response to PDGF
Fig. 3. Thymidine incorporation in HDMVEC and HUVEC is decreased by NADPH oxidase inhibitor. [3H]Thymidine incorporation was mea-
sured in untreated HDMVEC (0.5%) treated with (A) 10 ng/ml VEGF (V), (B) 5 ng/ml bFGF (bF) or (C) 5% FBS (5%) in the absence or
presence of 10 WM DPI (+DPI), 100 WM allopurinol (+Allo) or 500 WM L-NAME (+L). (D) [3H]Thymidine incorporation was measured in un-
treated HUVEC (0.5%) or in HUVEC treated with 5% FBS in the absence or presence of the same dose of inhibitors.
Fig. 4. VEGF-mediated chemotaxis of HCAEC is abrogated by NADPH oxidase inhibitors. A modi¢ed Boyden chamber was used to assess
migratory activity in control HCAEC or in HCAEC exposed to 50 ng/ml VEGF (V) in the absence or presence of (A) 10 WM DPI (V+DPI),
(B) 500 WM L-NAME (V+L-NAME) or 300 WM apocynin (V+Apo), (C) 100 WM allopurinol (V+Allo) or 250 WM AEBSF (V+AEBSF).
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[22], phenylephrine [23], and thrombin [8], as well as the hy-
pertrophic e¡ect of angiotensin II [10]. Moreover, the addition
of exogenous ROS to VSMC was reported to induce cell
proliferation [24], while suppression of ROS resulted in in-
creased apoptosis [25,26]. In contrast to these ¢ndings in
VSMC, little is known about the role of ROS in endothelial
cell growth and/or survival.
In the present study, we have demonstrated that the mito-
genic and chemotactic e¡ects of VEGF were abrogated by
three structurally unrelated inhibitors of NADPH oxidase,
but not by inhibitors of xanthine oxidase or NOS. We have
previously shown that VEGF does not induce ROS genera-
tion in HCAEC (Abid et al., unpublished observations). We
have demonstrated here that ROS generation in VEGF-
treated HCAEC is inhibited by DPI, but not by allopurinol
or L-NAME. Taken together, these ¢ndings suggest that
VEGF-mediated proliferation and migration of endothelial
cells are dependent upon ambient, rather than incremental,
levels of NADPH oxidase-derived ROS.
As an extension of the above ¢ndings, we have shown that
NADPH oxidase activity is also a critical determinant of
bFGF- and serum-induced endothelial cell proliferation. In-
deed, at higher concentrations of NADPH oxidase inhibitors,
thymidine uptake decreased well below control values, sug-
gesting that NADPH oxidase-derived ROS are required for
endothelial cell proliferation under both basal and stimulated
states. Finally, we have demonstrated that NADPH oxidase
inhibitors suppress the proliferation of multiple types of en-
dothelial cells. These results are the ¢rst to show that
NADPH oxidase activity is a universal requirement for endo-
thelial cell proliferation.
The mechanisms by which ROS mediate cell growth are
presently unknown. ROS have been shown to activate multi-
ple signaling pathways such as ERK1/2 [22,27] and Akt kinase
[28]. Activation of ERK1/2 and Akt has been implicated in
VEGF-induced endothelial cell growth and/or survival [29,30].
In addition, ROS have been shown to activate the transcrip-
tion factor, NFUB [31,32]. Increased activation of NFUB, in
turn, has been reported to increase endothelial cell survival
[33]. Whether one or more of these signaling pathways are
involved in mediating the e¡ect of NADPH oxidase-derived
ROS on endothelial cell proliferation and/or migration re-
mains to be determined.
The requirement of NADPH oxidase activity for endothe-
lial cell proliferation and migration may have important clin-
Fig. 5. Decrease in VEGF-mediated chemotaxis by NADPH oxidase
inhibitors is dose-dependent. Migration in control HCAEC (C) or
in HCAEC exposed to 50 ng/ml VEGF in the absence or presence
of (A) increasing doses of DPI or (B) increasing doses of AEBSF.
Fig. 6. ROS generation in VEGF-treated cells is inhibited by
NADPH oxidase inhibitor. Representative DCF £uorescence distri-
bution of untreated HCAEC (C) or VEGF-treated HCAEC in the
absence (V) or presence of 100 WM DPI (V+DPI), 500 WM
L-NAME (V+L-NAME) or 100 WM allopurinol (V+Allo).
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ical implications. The growth of tumors is dependent on new
blood vessel formation. In recent years, there has been an
e¡ort to develop novel anti-angiogenesis strategies that inhibit
tumor growth. For example, speci¢c inhibitors of matrix met-
alloproteinases, vasostatin [34], endostatin [35], angiostatin
[36,37], and anti-thrombin [38] have been shown to inhibit
angiogenesis. In addition, neutralizing antibodies that inhibit
the VEGF^VEGF receptor axis [39,40], and antisense target-
ing of bFGF and FGF receptor 1 [41] have been shown to
suppress tumor growth. The results of the present study sug-
gest that the NADPH oxidase complex may serve as a novel
target for anti-angiogenic therapy.
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